|
1
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cell, cancer and cancer stem cell. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Generali D, Buffa FM, Berruti A, et al:
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as
predictors of primary endocrine treatment response and resistance
in patients with breast cancer. J Clin Oncol. 27:227–234. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu M and Polyak K: Molecular
characterization of the tumour microenvironment in breast cancer.
Eur J Cancer. 44:2760–2765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heddleston JM, Zhizhong L, McLendon RE,
Hjelmeland AB and Rich JN: The hypoxic microenvironment maintains
glioblastoma stem cells and promotes reprogramming towards a cancer
stem cell phenotype. Cell Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xing F, Okuda H, Watabe M, et al:
Hypoxia-induced Jagged2 promotes breast cancer metastasis and
self-renewal of cancer stem-like cells. Oncogene. 30:4075–4086.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Conley SJ, Gheordunescu E, Kakarala P, et
al: Antiangiogenic agents increase breast cancer stem cells via the
generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iyer R, Fetterly G, Lugade A and Thanavala
Y: Sorafenib: a clinical and pharmacologic review. Expert Opin
Pharmacother. 11:1943–1955. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar
|
|
11
|
Siegel AB, Olsen SK, Magun A and Brown RS:
Sorafenib: Where do we go from here? Hepatology. 52:360–369. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang CJ, Yang JY, Xia W, et al: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100.
2011.PubMed/NCBI
|
|
14
|
Sharma A, Trivedi NR, Zimmerman MA,
Tuveson DA, Smith CD and Robertson GP: Mutant V599 EB-Raf regulates
growth and vascular development of malignant melanoma tumors.
Cancer Res. 65:2412–2421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar SM, Yu H, Edwards R, et al: Mutant
V600E BRAF increases hypoxia inducible factor-1alpha expression in
melanoma. Cancer Res. 67:3177–3184. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dontu G, Abdallah WM, Foley JM, et al: In
vitro propagation and transcriptional profiling of human mammary
stem/progenitor cells. Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ata N, Oku T, Hattori M, Fujii H, Nakajima
M and Saiki I: Inhibition by galloylglucose (GG6-10) of tumor
invasion through extracellular matrix and gelatinase-mediated
degradation of type IV collagens by metastatic tumor cells. Oncol
Res. 8:503–511. 1996.
|
|
18
|
Elkin M, Reich R, Nagler A, et al:
Inhibition of matrix metalloproteinase-2 expression and bladder
carcinoma metastasis by halofuginone. Clin Cancer Res. 5:1982–1988.
1999.PubMed/NCBI
|
|
19
|
Zervos EE, Shafii AE, Haq M and Rosemurgy
AS: Matrix metalloproteinase inhibition suppresses MMP-2 activity
and activation of PANC-1 cells in vitro. J Surg Res. 84:162–167.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Denkert C, Siegert A, Leclere A, Turzynski
A and Hauptmann S: An inhibitor of stress-activated MAP-kinase
reduces invasion and MMP-2 expression of malignant melanoma cells.
Clin Exp Metastasis. 19:79–85. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kargozaran H, Yuan SY, Breslin JW, et al:
A role for endothelial-derived matrix metalloproteinase-2 in breast
cancer cell transmigration across the endothelial-basement membrane
barrier. Clin Exp Metastasis. 24:495–502. 2007. View Article : Google Scholar
|
|
22
|
Eyler CE and Rich JN: Survival of the
fittest: Cancer stem cells in therapeutic resistance and
angiogenesis. J Clin Oncol. 10:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Plastaras JP, Kim SH, Liu YY, et al: Cell
cycle dependent and schedule-dependent antitumor effects of
sorafenib combined with radiation. Cancer Res. 67:9443–9454. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bonelli MA, Fumarola C, Alfieri RR, et al:
Synergistic activity of letrozole and sorafenib on breast cancer
cells. Breast Cancer Res Treat. 124:79–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimizu S, Eguchi Y, Kamiike W, et al:
Induction of apoptosis as well as necrosis by hypoxia and
predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer
Res. 56:2161–2166. 1996.PubMed/NCBI
|
|
26
|
Gupta-Abramson V, Troxel AB, Nellore A, et
al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin
Oncol. 26:4714–4719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kuo YC, Lin WC, Chiang IT, et al:
Sorafenib sensitizes human colorectal carcinoma to radiation via
suppression of NF-κB expression in vitro and in vivo. Biomed
Pharmacother. 66:12–20. 2012.PubMed/NCBI
|
|
29
|
Kasibhatla M, Steinberg P, Meyer J,
Ernstoff MS and George DJ: Radiation therapy and sorafenib:
Radiation therapy and sorafenib: clinical data and rationale for
the combination in metastatic renal cell carcinoma. Clin Genitourin
Cancer. 5:291–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soeda A, Park M, Lee D, et al: Hypoxia
promotes expansion of the CD133-positive glioma stem cells through
activation of HIF-1α. Oncogene. 28:3949–3959. 2009.PubMed/NCBI
|
|
31
|
Méndez O, Zavadil J, Esencay M, et al:
Knock down of HIF-1α in glioma cells reduces migration in vitro and
invasion in vivo and impairs their ability to form tumor spheres.
Mol Cancer. 9:1332010.
|
|
32
|
Wang Z, Shi Q, Wang Z, et al:
Clinicopathologic correlation of cancer stem cell markers CD44,
CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive
ductal carcinoma of breast: an immunohistochemistry-based pilot
study. Pathol Res Pract. 207:505–513. 2011.PubMed/NCBI
|
